Slavutsky I, Campos E, Cid M G, Larripa I
Departamento de Genética, Academia Nacional de Medicina, Buenos Aires, Argentina.
Anticancer Drugs. 1995 Dec;6(6):758-62. doi: 10.1097/00001813-199512000-00007.
Micronuclei (MN) induction by carboplatin, cis-diammine-1,1-cyclobutane decarboxylate platinum (II) (CBDCA), in B and T lymphocytes was studied by the MAC (morphology/antibody/chromosome) method which allows the immunologic identification of different cell lineages. An increased frequency of MN in B and T lymphocytes in CBDCA-treated cultures compared with controls was observed (p < 0.001). CBD cells were found to be more sensitive to CBDCA damage. CBDCA-treated cultures showed a decrease, albeit statistically non-significant, in the proportion of CBD interphasic and mitotic cells. Furthermore, higher MN frequencies in isolated lymphocytes than in whole blood in both control and CBDCA-treated cultures were observed.